Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy by Emily Hoffmann, Mirjam Gerwing, Tobias Krähling, Uwe Hansen, Katharina Kronenberg, Max Masthoff, Christiane Geyer, Carsten Höltke, Lydia Wachsmuth, Regina Schinner, Verena Hoerr, Walter Heindel, Uwe Karst, Michel Eisenblätter, Bastian Maus, Anne Helfen, Cornelius Faber, Moritz Wildgruber

“…In the low malignant 67NR model, ICI treatment also mediated vessel-stabilizing effects with decreased tumor perfusion and permeability, while ICI-treated 4T1 tumors exhibited increasing tumor perfusion with excessive vascular leakage. …”
Get full text

Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice by Francesca Carlino, Anna Diana, Antonio Piccolo, Anna Ventriglia, Vincenzo Bruno, Irene De Santo, Ortensio Letizia, Ferdinando De Vita, Bruno Daniele, Fortunato Ciardiello, Michele Orditura

“…Although breast cancer (BC) has been historically considered a “cold tumor”, exciting progress in the genomic field leading to the characterization of the molecular portrait and the immune profile of TNBC has opened the door to novel therapeutic strategies, including Immune Checkpoint Inhibitors (ICIs), Poly ADP-Ribose Polymerase (PARP) inhibitors and Antibody Drug Conjugates (ADCs). …”
Get full text

Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer by Davide Massa, Anna Tosi, Antonio Rosato, Valentina Guarneri, Maria Vittoria Dieci

“…Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors. …”
Get full text

A circadian rhythm-related gene signature for prognosis, invasion and immune microenvironment of breast cancer by Mei-Huan Wang, Xiao Liu, Qian Wang, Qian Wang, Hua-Wei Zhang, Hua-Wei Zhang

“…Background: Circadian dysregulation is linked to the onset and progression of cancer, but current knowledge of the role of circadian rhythm-related genes (CRRGs) in breast cancer (BC) is limited and incomplete. The purpose of this study was to investigate the potential role and immune-related prognostic significance of CRRGs in BC.Methods: The Cancer Genome Atlas breast cancer (TCGA-BRCA) genetic data were combined with 1369 CRRGs to create a model of BC prognosis-related CRRGs. …”
Get full text

Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications by Jun Yin, Tiezheng Gu, Norin Chaudhry, Nancy E. Davidson, Yi Huang, Yi Huang

“…Compared to highly immunogenic tumor types, such as melanoma or lung cancer, breast cancer has been viewed as an immunologically quiescent tumor which displays a relatively low population of tumor-infiltrating lymphocytes (TIL), low tumor mutational burden (TMB) and modest response rates to immune checkpoint inhibitors (ICI). …”
Get full text

Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer by Martina Dameri, Lorenzo Ferrando, Gabriella Cirmena, Claudio Vernieri, Giancarlo Pruneri, Alberto Ballestrero, Gabriele Zoppoli

“…In this review, we analyze available NGS platforms and clinical applications of multi-gene testing in breast cancer, with a focus on metastatic triple-negative breast cancer (mTNBC). …”
Get full text

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type by Md Abdus Subhan, Farzana Parveen, Hassan Shah, Satya Siva Kishan Yalamarty, Janaína Artem Ataide, Valdimir P. Torchilin

“…Breast cancer is a heterogeneous disease with different molecular subtypes. …”
Get full text

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis by Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti

“…Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. …”
Get full text

The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis by Liyuan Ke, Su Li, Hongxia Cui

“…Conclusion Meta-analysis revealed that the prognostic relevance of TMB in breast cancer is limited in scope. High TMB may be associated with longer survival only in ICIs-based treatment, but the association is not evident in non-ICIs-based treatment. …”
Get full text

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group by Khalid El Bairi, Harry R. Haynes, Elizabeth Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner, Juliana Ribeiro de Freitas, Daniel Sur, Luis Claudio Amendola, Masoumeh Gharib, Amine Kallala, Indu Arun, Farid Azmoudeh-Ardalan, Luciana Fujimoto, Luz F. Sua, Shi-Wei Liu, Huang-Chun Lien, Pawan Kirtani, Marcelo Balancin, Hicham El Attar, Prerna Guleria, Wenxian Yang, Emad Shash, I-Chun Chen, Veronica Bautista, Jose Fernando Do Prado Moura, Bernardo L. Rapoport, Carlos Castaneda, Eunice Spengler, Gabriela Acosta-Haab, Isabel Frahm, Joselyn Sanchez, Miluska Castillo, Najat Bouchmaa, Reena R. Md Zin, Ruohong Shui, Timothy Onyuma, Wentao Yang, Zaheed Husain, Karen Willard-Gallo, An Coosemans, Edith A. Perez, Elena Provenzano, Paula Gonzalez Ericsson, Eduardo Richardet, Ravi Mehrotra, Sandra Sarancone, Anna Ehinger, David L. Rimm, John M. S. Bartlett, Giuseppe Viale, Carsten Denkert, Akira I. Hida, Christos Sotiriou, Sibylle Loibl, Stephen M. Hewitt, Sunil Badve, William Fraser Symmans, Rim S. Kim, Giancarlo Pruneri, Shom Goel, Prudence A. Francis, Gloria Inurrigarro, Rin Yamaguchi, Hernan Garcia-Rivello, Hugo Horlings, Said Afqir, Roberto Salgado, Sylvia Adams, Marleen Kok, Maria Vittoria Dieci, Stefan Michiels, Sandra Demaria, Sherene Loi, The International Immuno-Oncology Biomarker Working Group

“…Abstract The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. …”
Get full text

Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer by Wenchang Lv, Yufang Tan, Xiaomei Zhou, Qi Zhang, Jun Zhang, Yiping Wu

“…Aberrant glycosylation, a post-translational modification of proteins, is regarded to engage in tumorigenesis and malignant progression of breast cancer (BC). The altered expression of glycosyltransferases causes abnormal glycan biosynthesis changes, which can serve as diagnostic hallmarks in BC. …”
Get full text

Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer by Sarah Sammons, Sarah Sammons, Sarah Sammons, Andrew Elliott, Romualdo Barroso-Sousa, Romualdo Barroso-Sousa, Saranya Chumsri, Antoinette R. Tan, George W. Sledge, Sara M. Tolaney, Sara M. Tolaney, Sara M. Tolaney, Evanthia T. Roussos Torres

“…BackgroundData supporting high tumor mutational burden (TMB-H) as a lone biomarker for an immune-responsive tumor microenvironment (TME) in metastatic breast cancer (MBC) are weak, yet tumor agnostic approval in TMB-H advanced tumors provides immune checkpoint inhibition (ICI) as a clinical option. …”
Get full text

Multiparametric chemical exchange saturation transfer MRI detects metabolic changes in breast cancer following immunotherapy by Emily Hoffmann, Daniel Schache, Carsten Höltke, Jens Soltwisch, Stephan Niland, Tobias Krähling, Klaus Bergander, Martin Grewer, Christiane Geyer, Linda Groeneweg, Johannes A. Eble, Thomas Vogl, Johannes Roth, Walter Heindel, Bastian Maus, Anne Helfen, Cornelius Faber, Moritz Wildgruber, Mirjam Gerwing, Verena Hoerr

“…Methods Tumor characteristics of highly malignant 4T1 and low malignant 67NR murine breast cancer models were investigated, and their changes during tumor progression and immune checkpoint inhibitor (ICI) treatment were evaluated. …”
Get full text

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer by Tinglin Yang, Wenhui Li, Tao Huang, Jun Zhou

“…The advent of immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized antitumor therapy. Programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are among the most promising targets for encouraging the immune system to eliminate cancer cells. …”
Get full text

Alterations in Progesterone Receptor Isoform Balance in Normal and Neoplastic Breast Cells Modulates the Stem Cell Population by María Sol Recouvreux, María Inés Diaz Bessone, Agustina Taruselli, Laura Todaro, María Amparo Lago Huvelle, Rocío G. Sampayo, Mina J. Bissell, Marina Simian

“…Flow cytometry and mammosphere assays revealed that in murine breast, overexpression of PRB leads to an increase in luminal and basal progenitor/stem cells. …”
Get full text

<it>AIB1 </it>gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines by Clarke Robert, Lou Mary, Lu Jyh-Feng, Dai Pu, Wong Lee-Jun C, Nazarov Viktor

“…<p>Abstract</p> <p>Background</p> <p>The poly Q polymorphism in <it>AIB1 </it>(amplified in breast cancer) gene is usually assessed by fragment length analysis which does not reveal the actual sequence variation. …”
Get full text

PTPRO-related CD8+ T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer by Hongmei Dong, Chaoyu Xie, Zhimeng Yao, Zhimeng Yao, Ruijun Zhao, Yusheng Lin, Yusheng Lin, Yusheng Lin, Yichen Luo, Shuanglong Chen, Yanfang Qin, Yexi Chen, Hao Zhang, Hao Zhang, Hao Zhang

“…Of note, the PTS could accurately predict the response to immune checkpoint inhibitors (ICIs).ConclusionPTPRO significantly impacts CD8+ T-cell infiltration in breast cancer, suggesting a potential role of immunomodulation. …”
Get full text

Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis by Tao Huang, Xianfu Sun, Xiaocao Meng, Mengdie Chen, Yapeng Li, Shengnan Du, Yingqiu Qi, Hong Ge

Get full text

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, obse... by Melissa Bersanelli, Elena Verzoni, Alessio Cortellini, Raffaele Giusti, Lorenzo Calvetti, Paola Ermacora, Marilena Di Napoli, Annamaria Catino, Valentina Guadalupi, Giorgia Guaitoli, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Guglielmini, Fabiana Perrone, Marco Maruzzo, Ernesto Rossi, Chiara Casadei, Vincenzo Montesarchio, Francesco Grossi, Mimma Rizzo, Maria Grazia Travagliato Liboria, Manlio Mencoboni, Fable Zustovich, Lucia Fratino, Caterina Accettura, Saverio Cinieri, Andrea Camerini, Mariella Sorarù, Paolo Andrea Zucali, Serena Ricciardi, Antonio Russo, Giorgia Negrini, Maria Chiara Banzi, Gaetano Lacidogna, Giuseppe Fornarini, Letizia Laera, Claudia Mucciarini, Matteo Santoni, Claudia Mosillo, Andrea Bonetti, Lucia Longo, Donata Sartori, Editta Baldini, Michele Guida, Mauro Iannopollo, Roberto Bordonaro, Maria Francesca Morelli, Pierosandro Tagliaferri, Massimiliano Spada, Anna Ceribelli, Rosa Rita Silva, Franco Nolè, Giordano Beretta, Petros Giovanis, Daniele Santini, Stefano Luzi Fedeli, Oriana Nanni, Evaristo Maiello, Roberto Labianca, Carmine Pinto, Alberto Clemente, Michele Tognetto, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Sebastiano Buti, Diana Giannarelli

Get full text

Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer by Miquel Ensenyat-Mendez, Javier I. J. Orozco, Pere Llinàs-Arias, Sandra Íñiguez-Muñoz, Jennifer L. Baker, Matthew P. Salomon, Mercè Martí, Maggie L. DiNome, Javier Cortés, Diego M. Marzese

“…Abstract Background Immune checkpoint inhibitors (ICI) improve clinical outcomes in triple-negative breast cancer (TNBC) patients. …”
Get full text